YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma
Pigment Cell & Melanoma Research · 2025
DOI: 10.1111/pcmr.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, 2025. Verfasst von Yan-Ling Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Drug Resistance, Neoplasm, Up-Regulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Yiyang Healthcare Charity Foundation.
Abstract (Originalsprache)
BET inhibitors have the potential to treat malignant tumors via the epigenetic modification mechanism. Although BET inhibitors show promise as anticancer agents for uveal melanoma (UM), the emergence of acquired resistance significantly limits their clinical efficacy. We developed isogenic OTX015‐resistant UM cell models (OMM2.3R and OMM2.5R) via exposure to escalating OTX015 concentrations (0.04–0.5 μM over 6 months). These resistant cells demonstrated reduced sensitivity to OTX015‐induced cytotoxicity. Moreover, the migratory ability of resistant cells was less affected by OTX015 compared to parental cells. Transcriptome analysis revealed an upregulation of YAP‐activated genes in resistant cells. Notably, OTX015‐resistant cells retained sensitivity to YAP inhibition via shRNA or pharmacological inhibitors. This study establishes YAP activation as a novel compensatory mechanism driving BET inhibitor resistance in UM. These findings position YAP inhibition as a potential therapeutic target to overcome BET inhibitor resistance, with clinical translational potential for resistant UM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
- Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
ORCID-Profile: Yan-Ling Zhou
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Yiyang Healthcare Charity Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y. L., Liu, X. L., Huang, S. S., Zhang, G. M., Jin, X. Y., Chen, L., Yu, L., & Li, Y. L. (2025). YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.70036
Vancouver
Zhou YL, Liu XL, Huang SS, Zhang GM, Jin XY, Chen L, et al. YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma. Pigment Cell & Melanoma Research. 2025. doi:10.1111/pcmr.70036
BibTeX
@article{Zhou2025,
author = {Zhou, Yan-Ling and Liu, Xiao-Lian and Huang, Si-Si and Zhang, Gui-Ming and Jin, Xuan-Yu and Chen, Liang and Yu, Le and Li, Yi-Lei},
title = {YAP Upregulation Contributes to Acquired Resistance to BET Inhibitors in Uveal Melanoma},
journal = {Pigment Cell & Melanoma Research},
year = {2025},
doi = {10.1111/pcmr.70036}
}
EUVIMED